A new federal grant opportunity supporting a ‘Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator’ initiative has been issued by the U.S. Department of Health and Human Services Assistant Secretary for Preparedness and Response (HHS/ASPR).
The program is a novel collaborative model designed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline, and is a component of the National Strategy for Combating Antimicrobial Resistant Bacteria.
Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development.
This Accelerator for CARB will be focusing only on antibacterial products, working in tandem with the medical countermeasure accelerator efforts of Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID).
BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to Accelerator grant recipients.
Further details are available via Funding Opportunity Number: EP-IDS-16-001. The closing date for applications is April 15, 2016
